IRVINE, Calif.--(BUSINESS WIRE)--AcuFocus (www.AcuFocus.com), maker of an innovative corneal inlay that may revolutionize the treatment of near vision loss (presbyopia), today announced significant procedural growth since 2010 with the global launch of the KAMRA inlay and an investment by leading medical technology company, Medtronic. AcuFocus is currently selling the KAMRA inlay in Europe, the Middle East, South America, and Asia-Pacific.
“This has been a tremendous year for growth in all areas of our business,” said Ed Peterson, AcuFocus President and Chief Executive Officer. “We’re thrilled by the enthusiastic response we’ve received from investors, including Medtronic, and are proud to have them as a strategic investor.”
“Medtronic is committed to advancing healthcare by investing in innovative technologies and new markets. AcuFocus’ strong track record of innovation in ophthalmology and strong market position align them well with our mission to bring life-enhancing therapies to patients around the world,” said Steve Oesterle, MD, Senior Vice President for Medicine and Technology at Medtronic.
“Medtronic is one of the world’s largest medical technology companies, and now they are able to enter the ophthalmology space at the right time,” commented Richard Lindstrom, MD, Minnesota Eye Consultants.
AcuFocus has invested in over 10 years of research and development, with more than 1,000 patients participating in its worldwide clinical trials. The KAMRA™ inlay received CE mark for use in the European Union in 2005 and is an investigational device under IDE in the United States. The device provides a revolutionary treatment option for near vision loss, or presbyopia, which affects 1.5 billion people worldwide. In 2010, AcuFocus commercially launched internationally with tremendous success. To date, there have been over 5,000 KAMRA inlays implanted globally with great results.
About the KAMRA Inlay and the AcuTarget™ Diagnostic and Surgical Guidance System
The KAMRA inlay is an intra-corneal inlay designed to create a small aperture effect, allowing the eye to see near and intermediate objects more clearly. By applying the “depth-of-focus” principle commonly used in photography, the KAMRA inlay controls light transmission allowing only central rays to reach the retina through a fixed 1.6 mm aperture. The KAMRA inlay is placed under a LASIK-type flap. The AcuTarget Diagnostic and Surgical Guidance system is an exclusive, proprietary device used to guide surgeons on proper surgical placement of the KAMRA inlay, ensuring precise, predictable and repeatable implantation for best outcomes and overall patient satisfaction.
The KAMRA inlay has received CE mark for use in the European Union and is an investigational device under Investigational Device Exemption (IDE) in the United States.
To learn more about the KAMRA inlay please visit www.KAMRA.com.
Presbyopia, a part of the normal aging process, reduces the ability of the eye to focus on near objects. This condition occurs when the crystalline lens of the eye loses its flexibility, making it difficult to focus on close objects. Presbyopia may seem to occur suddenly, but the actual loss of flexibility takes place over a number of years, usually becoming noticeable in the early to mid-40s. Presbyopia is not a disease and it cannot be prevented. Traditionally, most people with presbyopia use reading glasses to improve their near vision.
AcuFocus, Inc., a privately held company located in Irvine, California, is developing the KAMRA inlay for the treatment of near vision loss (presbyopia). For more information about AcuFocus please visit www.AcuFocus.com.